We suggest the use of metformin and SGLT-2 inhibitors as a first-line long-term treatment in patients with type 2 diabetes and eGFR < 60 ml/min, without previous cardiovascular events/heart failure. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.